Inflammatory Bowel Disease and Gut Microbiota

Current Strategies and Future Prospects in Nanomedicine
1. Auflage 2025
ISBN: 978-1-77491-936-1
Verlag: Apple Academic Press

Buch, Englisch, 612 Seiten, Format (B × H): 161 mm x 240 mm, Gewicht: 1077 g

This new volume delves into the extensive new research on inflammatory bowel disease (IBD) and gut microbiota that has led to effective therapeutic interventions. Highlighting novel methodologies and innovative treatment approaches, the book provides a comprehensive investigation of IBD, exploring the significance of gut microbiota and investigating the fundamental role of microbial imbalances in the initiation and progression of inflammatory processes as well as the prominent therapeutic consequences of restoring microbial homeostasis. From nanoparticle-based drug delivery systems that advance the bioavailability of the medicament to the use of bio-nanosensors for early detection of disease, the book covers a broad spectrum of inventions that hold potential for revolutionizing IBD treatment. The authors look at the impact of nutraceuticals, probiotics, prebiotics, functional foods, oral siRNA-based nanomedicine, and other novel drug delivery systems on gut microbiota for the management of IBD. The book also explores the role of reactive oxygen species (ROSs), superoxide dismutases (SODs), and inflammation in association with gut microbiota and IBD.

Zielgruppe

Academic and Postgraduate

Autoren/Hrsg.

Mishra, Neeraj

Ashique, Sumel

Garg, Ashish

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Medizin, Gesundheit: Sachbuch, Ratgeber
• Technische Wissenschaften Technik Allgemein Nanotechnologie
• Technische Wissenschaften Maschinenbau | Werkstoffkunde Maschinenbau Mechatronik, Mikrosysteme (MEMS), Nanosysteme

Inhaltsverzeichnis

1. Introduction to Gut Microbiota and Inflammatory Bowel Disease: A Systematic Review 2. Pathogenesis of Gut Microbiota in Inflammatory Bowel Disease 3. Impact of Nutraceuticals on Gut Microbiota for the Management of Inflammatory Bowel Disease 4. Targeting Gut Microbiota with a Novel Drug Delivery System to Treat Inflammatory Bowel Disease 5. Management of Gut Microbiota-Derived Bacterial Metabolites Induced Inflammatory Bowel Disease 6. Correlation Between Host Genetics and Gut Microbiota in Inflammatory Bowel Disease 7. Oral siRNA-Based Nanomedicine for the Treatment of Inflammatory Bowel Disease 8. Site-Specific Targeted Novel Drug Delivery System for the Management of Inflammatory Bowel Disease 9. Surface-Modified Lipid Nanoparticle-Mediated Site-Specific Drug Delivery for Inflammatory Bowel Disease 10. Interplay Between Autophagy, Gut Microbiota, and Inflammatory Bowel Disease 11. Role of Reactive Oxygen Species, Superoxide Dismutases, and Inflammation in Association with Gut Microbiota and Inflammatory Bowel Disease 12. Composition of Gut Microbiota Dysbiosis and Functional Food to Treat Inflammatory Bowel Disease 13. Age-Related Gut Dysbiosis and Its Impact on Inflammatory Bowel Disease 14. Impact of Diseased Condition on Gut Microbiota in Inflammatory Bowel Disease 15. Role of Probiotics and Prebiotics in Inflammatory Bowel Disease 16. Application of Natural Products to Target Gut Microbiota for Inflammatory Bowel Disease Management 17. Future Prospects and Patents of Nanomedicines in Treating Inflammatory Bowel Disease

Über Autor(innen)

Neeraj Mishra, PhD, is a Professor at the Amity Institute of Pharmacy, Gwalior, India. He has 20 years of teaching and research experience. A brand ambassador at Bentham Science, he has published more than 100 papers on recent concepts of novel drug delivery systems, oral delivery of synbiotics, localized drug delivery, targeted and controlled drug delivery of nanocarriers/microparticles for the treatment of breast and colon cancer, and neurodegenerative disorders. He has also written more than 15 books and 25 book chapters and has been granted several patents. He was a recipient of an Indian Council of Medical Research Senior Research Fellowship and a Distinguished Professor Award from the Indian Department of Science and Technology, National Science and Technology Management Information System, Synergizing Pharma Academic-Industry Collaboration Systems.

Sumel Ashique, MPharm, is a Research Scholar at the School of Pharmaceutical Sciences at Lovely Professional University, Punjab, India, where he is pursuing his PhD. His research area is probiotics, postbiotics, gut microbiota, and inflammatory disorders. With knowledge in drug delivery, nanotechnology, and targeted treatment strategy, he has four years of teaching experience and has published book chapters with international publishers and over 100 papers in accredited reputed journals. He has also six granted intellectual property (IP) patents from IP India and Australia. He is currently editing 13 books with Apple Academic Press, CRC Press, Taylor and Francis, and others.

Ashish Garg, PhD, is a Professor at the Guru Ramdas Khalsa Institute of Science and Technology (Pharmacy), Jabalpur, M.P., India. He has around ten years of teaching and research experience and has 80 publications in national and international journals of repute. He has authored 27 book chapters and edited several books on recent concepts of nanotechnology, novel drug delivery systems, cancer targeting, etc. Dr. Garg has been granted three international patents and has published three Indian patents. He also acts as an editorial board member and reviewer for several journals.